People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gossamer Bio, Inc. | — | Biotechnology | Series D+ | $632.6M | $3.2B | 2018 |
Otello Stampacchia, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Otello Stampacchia, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Richard Lim | 1 | 14 |
| Faheem Hasnain | 1 | 5 |
| Michael Yi | 1 | 4 |
| Christian Waage | 1 | 2 |
| Renee Gala | 1 | 2 |
| Laura Carter, Ph.D. | 1 | 1 |
| Joshua Bilenker, M.D. | 1 | 1 |
| Jill Howe | 1 | 1 |
| Sheila Gujrathi, M.D. | 1 | 1 |
| Sandra Milligan, M.D., J.D. | 1 | 1 |
| Russell Cox | 1 | 1 |
| Bryan Giraudo | 1 | 1 |
| Richard Aranda, M.D. | 1 | 1 |
| Caryn Peterson | 1 | 1 |
| Thomas Daniel, M.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.